Leukemia, a disease arising from genetic aberrations in hematopoietic cells, has traditionally been studied through its varied mutations and associated molecular pathways. However, patients harboring vastly different genetic changes often manifest convergent gene expression profiles and respond similarly to select treatments, hinting at an underlying commonality. The question that perplexed researchers for years was whether a hidden cellular principle could unify these seemingly heterogeneous forms of leukemia.

In a pioneering collaboration, the laboratories of Dr. Joshua Riback and Dr. Margaret Goodell at Baylor College of Medicine embarked on a mission to elucidate this mystery by probing the physicochemical underpinnings of leukemia. Riback, notable for his expertise in protein phase separation mechanisms, teamed with Goodell, a distinguished figure in hematopoietic stem cell biology and leukemia pathogenesis. Their combined efforts represented a confluence of physics and molecular biology, aiming to link cellular biophysics with oncogenic gene regulation.

The breakthrough came with graduate student Gandhar Datar’s meticulous high-resolution microscopy work, revealing that nuclei from leukemia cells housed distinct, bright puncta—structures entirely absent in normal hematopoietic nuclei. These structures, described as “coordinating bodies” or C-bodies, represented phase-separated nuclear compartments enriched with mutant leukemia proteins alongside a consortium of wild-type proteins. This ensemble co-localized molecular constituents critical to the sustained activation of leukemia-driving gene networks.

Phase separation, a principle borrowed from physical chemistry describing how immiscible substances segregate to form droplets—much like oil partitioning itself in water—provided the conceptual framework to understand C-bodies. Within the cell nucleus, these membraneless condensates operate as regulatory microenvironments, organizing and concentrating factors required for oncogenic transcriptional programs. Their formation depends sensitively on protein-protein and protein-RNA interactions tuned just so—akin to a delicate molecular equilibrium producing precise droplet consistency.

Perhaps most striking was the observation that leukemias driven by entirely distinct mutations nonetheless formed C-bodies with nearly indistinguishable biophysical properties. This revelation emerged from innovative quantitative assays developed by the Riback Lab, demonstrating uniform droplet behavior despite heterogeneous mutational landscapes. The implication is profound: diverse genetic lesions funnel into a shared biophysical substrate that maintains the malignant state.

Further experimental manipulation lent credence to the functional indispensability of C-bodies. Genetic perturbations disrupting the phase separation capacity of leukemia-associated proteins led to disintegration of these nuclear condensates. This collapse halted cancer cell proliferation and promoted differentiation into mature, non-malignant blood cells. Complementing genetic approaches, pharmacological agents capable of dissolving these droplets recapitulated similar therapeutic effects, highlighting the condensates as viable drug targets.

The universality of this phenomenon was confirmed through extensive analyses utilizing human leukemia cell lines, transgenic mouse models, and primary patient samples, solidifying the central role of C-bodies in disease biology. Moreover, the presence of these nuclear compartments in patient cells provided a tangible morphological hallmark that could bridge mechanistic insights to practical diagnostics and treatment strategies.

By framing leukemia mutations around a shared, phase-separated condensate, this study introduces an entirely new dimension to cancer therapeutics. Instead of targeting individual genetic aberrations—which are numerous and complex—future interventions could focus on modulating the physical properties of C-bodies, effectively undermining a fundamental organizational hub of the leukemia transcriptome. Such an approach promises a broader spectrum of efficacy and a potential reduction in resistance mechanisms that plague mutation-specific drugs.

Beyond leukemia, the discovery raises the tantalizing prospect that other diseases, particularly neurodegenerative disorders like ALS, may similarly rely on formation of biophysically analogous droplet-like nuclear or cytoplasmic structures. This opens vistas for generalized therapeutic paradigms grounded in the physics of biomolecular condensates, rather than exclusively on their molecular composition.

This landmark discovery was enabled by multidisciplinary collaboration and supported by numerous institutions committed to cancer research. The intersection of molecular biology, biophysics, and clinical science in this work exemplifies the future direction of biomedical research—where comprehending the physical nature of cellular organization yields novel insights and treatment avenues that transcend conventional genetics alone.

As we gain deeper understanding of how C-bodies orchestrate oncogenic programs, the vision of therapies that dissolve these condensates and restore regulatory balance comes into sharper focus. This physical targeting strategy could usher in a new era in leukemia care, moving from fragmented mutation-specific approaches toward a unified treatment grounded in cellular biophysics.

The revelation of C-bodies heralds a paradigm shift, turning the once elusive intracellular complexity of leukemia into a decipherable and targetable physical framework. In doing so, it shines a light on the intricate dance between physics and biology that governs disease—and offers hope for innovations capable of transforming patient outcomes in leukemia and beyond.

Subject of Research: Animals

Article Title: Disparate Leukemia Mutations Converge on Nuclear Phase-Separated Condensates

News Publication Date: 4-Nov-2025

Web References: DOI: 10.1016/j.cell.2025.10.010

Keywords: Life sciences, Biochemistry, Biophysics, Cell biology, Developmental biology, Molecular biology

Ulrich Steidl, M.D., Ph.D., a pioneering investigator in the molecular and cellular basis of blood disorders, has been inducted into the prestigious Association of American Physicians (AAP). This venerable institution, with a legacy spanning nearly a century and a half, represents the pinnacle of physician-scientist excellence, honoring those whose research innovation profoundly advances medical science. Dr. Steidl serves as professor and chair of cell biology at the Albert Einstein College of Medicine and acts as deputy director at the Montefiore Einstein Comprehensive Cancer Center, a National Cancer Institute (NCI)-designated facility renowned for its research and clinical care.

The announcement, made on April 26, recognizes Dr. Steidl’s exemplary contributions to understanding the pathogenesis of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), two hematologic malignancies with complex stem cell origins. His election to the AAP underscores his stature as a leader synthesizing basic molecular insights with translational strategies aimed at improving patient outcomes. According to the AAP, membership is conferred upon individuals who demonstrate exceptional physician-led scientific leadership and groundbreaking research accomplishments.

At the heart of Dr. Steidl’s research lies a profound investigation into the biology of hematopoietic stem cells that give rise to MDS and ultimately AML. His work, driven by robust NIH and private funding, delves into the molecular abnormalities within pre-leukemic stem cells — the precursors to malignant clones. By elucidating the cellular pathways and genetic alterations underpinning the transition from pre-leukemic to full leukemic states, Dr. Steidl has charted pathways that are critical for early intervention and targeted therapy development. This insight is shifting paradigms in hematologic oncology, moving from symptom management to molecularly precise disruption of disease progression.

Significantly, Dr. Steidl was among the first researchers to demonstrate the defective nature of hematopoietic stem cells in MDS, a disorder recognized as a precursor to AML. This conceptual breakthrough, published in high-impact journals such as Nature Medicine, revolutionized the understanding of how these diseases originate and evolve at the stem cell level, challenging previously accepted models. Through this work, he has laid the foundation for novel therapeutic agents currently undergoing clinical trials, aiming to eradicate the aberrant stem cell populations that drive disease perpetuation and relapse.

The translational arc of Dr. Steidl’s research is underscored by his receipt of the National Cancer Institute’s Outstanding Investigator Award in 2021 — a competitive grant that supports sustained, innovative research endeavors. This award, accompanied by a seven-year funding commitment of $7 million, enables his laboratory to probe deeper into the genetic and epigenetic mechanisms governing stem cell transformation. It also facilitates the development and testing of drug candidates designed to selectively target malignant stem cells without compromising normal hematopoiesis, a critical balance in preventing treatment-related toxicity.

In addition to his laboratory investigations, Dr. Steidl holds the Edward P. Evans Endowed Professorship for Myelodysplastic Syndromes and serves as interim director of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine. His leadership roles emphasize his commitment to fostering interdisciplinary collaboration and advancing regenerative approaches to hematologic disease. The Gottesman Institute represents a hub where stem cell biology, molecular genetics, and translational medicine converge to create innovative therapeutic strategies.

Dr. Steidl’s work is characterized by the seamless integration of cutting-edge genomic technologies, including single-cell RNA sequencing and CRISPR-Cas9 gene editing, with classical hematology. This combination allows his team to dissect the cellular heterogeneity within MDS and AML, identifying rare populations of cells that resist conventional chemotherapy and contribute to disease relapse. These findings have profound implications for the design of next-generation therapeutics capable of achieving long-term remission or cure.

Yaron Tomer, M.D., the Marilyn and Stanley M. Katz Dean at Einstein and chief academic officer at Montefiore Einstein, lauded Dr. Steidl’s induction into the AAP as a testament to his scientific rigor and translational impact. He highlighted Dr. Steidl as a physician-scientist whose research exemplifies how mechanistic studies at the molecular level can directly inform clinical practice. This bridge between bench and bedside is essential for addressing the unmet needs of patients afflicted by aggressive hematologic cancers.

More than 150 peer-reviewed publications bear Dr. Steidl’s name, illustrating the depth and breadth of his contributions to cancer biology. His research not only advances fundamental understanding but also influences clinical protocols, as several experimental therapies originating from his findings are in human trials. These trials evaluate compounds targeting aberrant survival pathways and stem cell self-renewal mechanisms, reflecting a new era of precision medicine in blood cancers.

The Montefiore Einstein Comprehensive Cancer Center, where Dr. Steidl is a deputy director, represents a model institution that merges scientific discovery with patient-centered care. NCI-designated since 1972, the center serves one of the nation’s most diverse populations, with a deliberate focus on reducing health disparities through inclusive research and community engagement. Dr. Steidl’s appointment to this leadership cadre reinforces the center’s commitment to excellence in cancer stem cell research.

Among the distinguished cohort of previous Albert Einstein College of Medicine faculty elected to the AAP are renowned physician-scientists who have made landmark contributions across various disciplines. The induction of Dr. Steidl continues this legacy of scientific achievement and highlights the institution’s role as a breeding ground for innovation in medical research.

Dr. Steidl expressed profound gratitude for the recognition, acknowledging the collaborative environment at Einstein, the inspiration derived from patients, and the support from colleagues and trainees. His statement reflects a dedication not only to advancing scientific frontiers but also to mentoring the next generation of physician-scientists who will carry forward the torch of translational research.

In sum, Dr. Ulrich Steidl’s election to the Association of American Physicians underscores his seminal role in uncovering the molecular drivers of MDS and AML, shaping new therapeutic landscapes, and exemplifying the integration of rigorous science with compassionate clinical care. His work heralds promising directions for the treatment of complex blood malignancies, emphasizing early detection and targeted intervention at the stem cell level. As the field evolves towards more personalized and effective therapies, Dr. Steidl’s discoveries continue to illuminate the path forward.

Subject of Research: Molecular and cellular mechanisms underlying myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), with emphasis on the biology of pre-leukemic and leukemic stem cells.

Article Title: Ulrich Steidl, M.D., Ph.D., Joins Association of American Physicians for Pioneering Work in Blood Stem Cell Research

News Publication Date: April 26, 2024

Web References:

• Faculty profile: https://einsteinmed.edu/faculty/11118/ulrich-g-steidl
• Montefiore Einstein Comprehensive Cancer Center: https://montefioreeinstein.org/cancer
• Albert Einstein College of Medicine: https://einsteinmed.edu

References:

• Steidl U, et al. “Myelodysplastic syndromes arise from hematopoietic stem cells with molecular defects.” Nature Medicine. 2018. https://www.nature.com/articles/s41591-018-0267-4

Image Credits: Albert Einstein College of Medicine

Keywords: Stem cell research, Cancer research, Clinical research, Hematologic malignancies, Myelodysplastic syndromes, Acute myeloid leukemia, Translational research, NIH Outstanding Investigator Award, Molecular biology, Targeted therapy, Precision medicine

Recent groundbreaking research has elucidated a fundamental metabolic reprogramming in murine hematopoietic stem and progenitor cells (HSPCs) carrying the Dnmt3a^R878H/+ mutation— a murine analog of the human DNMT3A^R882H/+ variant. These mutant HSPCs exhibit notably enhanced mitochondrial respiratory activity compared to their wild-type counterparts. This metabolic shift suggests that mutant stem cells harness augmented oxidative phosphorylation as a mechanism to sustain their clonal expansion, thereby gaining a formidable selective advantage within the bone marrow niche. This discovery opens an intriguing avenue for therapeutic intervention by targeting cellular metabolism to counteract clonal dominance.

One of the most compelling aspects of this work lies in the application of metformin, a well-established anti-diabetic medication known to inhibit mitochondrial respiration. Treatment of Dnmt3a^R878H/+ mutant HSPCs with metformin dramatically attenuated their enhanced mitochondrial function, thereby diminishing their competitive superiority over wild-type cells. This intervention demonstrates, for the first time, that suppression of mitochondrial bioenergetics can directly reverse the clonal fitness advantage conferred by a prevalent driver mutation in clonal hematopoiesis.

The study employed a multi-omic approach, integrating epigenomic and transcriptomic analyses, to unravel the molecular mechanisms underlying metformin’s effects on mutant HSPCs. Intriguingly, metformin treatment elevated the methylation potential within Dnmt3a^R878H/+ cells, effectively restoring the disrupted DNA methylation landscape characteristic of these mutants. Notably, the aberrant CpG methylation patterns and histone H3 lysine 27 trimethylation marks, which are hallmarks of epigenetic dysregulation in these cells, were significantly normalized following metformin administration. These epigenetic corrections might underlie the observed attenuation of clonal dominance.

Extending these findings beyond murine models, the researchers utilized prime editing technology to generate human DNMT3A^R882H HSPCs and demonstrated that metformin similarly reduced their competitive proliferation advantage. This translational validation underscores the therapeutic promise of metformin as a candidate for clinical repurposing in the prevention of DNMT3A R882-mutant clonal hematopoiesis in humans. The ability to modulate mutant stem cell fitness without invoking cytotoxicity could pave the way for safe and feasible long-term intervention strategies.

The implications of targeting mitochondrial metabolism to curb clonal hematopoiesis are far-reaching. Given that clonal expansions driven by DNMT3A mutations increase the risk for both hematologic cancers and systemic inflammatory diseases, metformin’s potential to interfere with these pathological trajectories is particularly significant. This class of metabolic modulators could serve both as preventive agents and adjunctive therapies, possibly forestalling progression to frank malignancy or ameliorating associated inflammatory states.

A remarkable aspect of this study is its convergence on metabolism-epigenetics crosstalk within hematopoietic stem cell biology. The Dnmt3a mutation not only endows cells with metabolic advantages but simultaneously disrupts DNA methylation, a fundamental epigenetic regulatory mechanism. By reversing metabolic alterations, metformin restores epigenetic integrity, suggesting feedback loops between energetic states and chromatin modification landscapes. This insight illuminates how metabolic interventions might epigenetically reprogram mutant stem cells back toward a more normal state.

Furthermore, the choice of metformin adds substantial clinical feasibility to this approach. As an extensively used, well-tolerated oral medication with a robust safety profile in diabetic and non-diabetic populations alike, metformin could be rapidly deployed in clinical trials targeting clonal hematopoiesis. Its established pharmacokinetics and minimal side effect burden lower barriers that often delay translational application of novel drug candidates in oncology and hematology.

The study’s meticulous multi-omics profiling uncovers a complex signature of metabolic and epigenetic changes accompanying DNMT3A-mutant clonal expansion. These data provide a valuable resource for further dissecting the molecular pathology of clonal hematopoiesis and identifying additional targets for therapeutic intervention. Importantly, the reversal of these perturbations by metformin signals that clonal fitness may be pharmacologically pliant, challenging prior notions that mutant HSC expansion is an irreversible process.

While these findings offer a compelling preclinical rationale for metformin, further clinical investigation is imperative. Longitudinal studies assessing metformin’s capacity to attenuate clonal expansion and delay onset of hematologic malignancies or inflammatory comorbidities will be crucial. Additionally, exploring whether similar metabolic dependencies exist in other clonal hematopoiesis driver mutations could broaden the therapeutic relevance of mitochondrial targeting.

In summary, this pioneering body of work identifies mitochondrial respiration as a critical metabolic vulnerability of Dnmt3a^R878H/+ mutant HSPCs that can be exploited therapeutically using metformin. By restoring epigenetic homeostasis and abrogating the mutant cells’ competitive edge, metformin emerges as a promising agent to intercept mutant clone expansion, potentially preventing devastating downstream consequences of clonal hematopoiesis in aging populations. The study heralds an exciting frontier where metabolic modulation converges with epigenetic therapy to tame the roots of blood cancer and age-associated disorders.

This research underscores a paradigm shift in how we conceptualize clonal hematopoiesis—not merely as a genetic drift phenomenon but as a metabolically and epigenetically orchestrated process amenable to pharmacological intervention. The prospect of repurposing an established drug to impede clonal progression holds transformative potential for public health, particularly in light of the escalating prevalence of clonal hematopoiesis with aging. As this field accelerates, metabolic and epigenetic therapies may become essential tools in preventive hematology.

Subject of Research: Clonal hematopoiesis driven by DNMT3A mutations and the metabolic and epigenetic mechanisms underlying clonal expansion; therapeutic intervention using metformin.

Article Title: Metformin reduces the competitive advantage of Dnmt3a^R878H HSPCs.

Article References:
Hosseini, M., Voisin, V., Chegini, A. et al. Metformin reduces the competitive advantage of Dnmt3a^R878H HSPCs. Nature (2025). https://doi.org/10.1038/s41586-025-08871-w

Image Credits: AI Generated